Vulvovaginal candidiasis is an infection of the estrogenised vagina and vestibulum which can also extend to the outer sides of the labia minora, the labia majora, the intercrural-region and the perianal region.
75% of women are affected at least once during their lifetime es. 90% of those affected are considered uncomplicated and Candida (fungus) is the cause.
Resistance to Candida treatment is a major and growing problem, a sharp increase has been seen in recent decades.
Nyvigan (nystatin) is a combination treatment (pessaries + cream) for the treatment of vulvovaginal Candida.
In vitro and in vivo studies show that nystatin has a good effect and there has been no development of resistance in Candida strains.
In addition Nyvigan offers:
Nyvigan (nystatin), Ointment 100 000 IU/g + vaginal tablets 100 000 IU, Rx, EF.
ATC code: G01AA01
Therapeutic indications: Nyvigan is indicated for the treatment of vulvovaginal candidiasis in adults. Please ensure compliance with official guidelines on correct use of antimycotics.
Dosing (ointment): twice daily to the infected skin areas on the outer areas of the genitals.
Dosing (vaginal tablets): one or two vaginal tablets once daily.
Storage: do not store above 25°C. Vaginal tablets should be stored in the original package, in order to protect from light.
Package information: combination pack with 25 g ointment (tube) + 6 vaginal tablets (blisters).
For full information regarding prescription and SPC (November 2020) please see www.fass.se
Please confirm that you are a healthcare professional